NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
TELA
TELA Bio, Inc.
TELA has the edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TELA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
TELA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TELA PE Valuation
TELA has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TELA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TELA's losses to shrink, with revenue holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TELA on earnings quality, reporting a profit while its opponent remains loss making.
TELA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.74 | +$0.09 |
| Q2 2026 | -$0.77 | +$0.29 |
| Q1 2026 | -$0.79 | +$0.56 |
| Q4 2025 | -$0.83 | +$0.50 |
| Q3 2025 | -$0.83 | +$0.83 |
| Q2 2025 | -$1.06 | +$0.63 |
| Q1 2025 | -$1.35 | +$0.29 |
| Q4 2024 | -$1.33 | +$0.71 |
TELA is still losing money, but far less than before: $0.74 per share over the past year, against $2.87 at its worst in late 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TELA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TELA on profitability, with a higher operating margin.
TELA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | -8.4% |
| Q2 2026 | $19.3M | -4.5% |
| Q1 2026 | $19.1M | +2.9% |
| Q4 2025 | $20.9M | +18% |
| Q3 2025 | $20.7M | +9.1% |
| Q2 2025 | $20.2M | +26% |
| Q1 2025 | $18.5M | +12% |
| Q4 2024 | $17.6M | +3.8% |
TELA's revenue has held roughly level: $19M last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | -1.9 points |
| Q2 2026 | -48% | -3.2 points |
| Q1 2026 | -55% | +1.3 points |
| Q4 2025 | -32% | +16 points |
| Q3 2025 | -37% | +13 points |
| Q2 2025 | -45% | +27 points |
| Q1 2025 | -57% | -28 points |
| Q4 2024 | -47% | +25 points |
TELA's operating margin was −38% last quarter, down 1.9 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TELA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TELA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.7M | -$2.8M |
| Q2 2026 | -$9.4M | -$1.4M |
| Q1 2026 | -$11.3M | -$1.5M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$5.9M | +$3.2M |
| Q2 2025 | -$8M | +$3M |
| Q1 2025 | -$9.8M | +$4.9M |
| Q4 2024 | -$7.8M | +$3.5M |
TELA has burned cash in almost every quarter: −$34M over the past year, against −$32M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TELA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TELA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +275K shares |
| 1 year | +27% | +12.3M shares |
| 3 years | +148% | +34.4M shares |
| 5 years | +299% | +43.2M shares |
| Available history | +406% | +46.3M shares |
TELA has 58M diluted shares, up 27% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TELA Net Leverage
TELA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TELA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.7 | Neutral |
| Stochastic | 25.3 | Neutral |
TELA's weekly RSI is 48 (neutral) and its Stochastic is 25 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TELA PE vs Healthcare Sector
TELA has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over TELA on trend strength, trading above more of its moving averages.
TELA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 13% below |
| 20 week MA | $0.88 | 2.3% below |
| 50 week MA | $0.88 | 2.3% below |
| 100 week MA | $1.34 | 36% below |
| 200 week MA | $4.07 | 79% below |
TELA is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over TELA on returns for 2026, with the stronger performance.
TELA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.7 | $16.0 | +26% |
| 2021 | $16.0 | $12.5 | -22% |
| 2022 | $12.5 | $11.3 | -10% |
| 2023 | $11.3 | $6.62 | -41% |
| 2024 | $6.62 | $2.91 | -56% |
| 2025 | $2.91 | $1.14 | -61% |
| 2026 YTD | $1.14 | $0.86 | -25% |
TELA has finished five years in a row lower, and it's down 25% so far in 2026.